Wegovy for Binge Eating Disorder: What the Evidence Actually Shows

BED is not diagnosed by body weight

Binge-eating disorder is a psychiatric diagnosis with criteria defined in the DSM-5-TR. A qualified clinician should assess recurrent episodes, loss of control, associated features, distress, frequency, duration, compensatory behaviors, medical status, and other psychiatric conditions. Obesity alone does not establish BED. See the American Psychiatric Association DSM-5-TR resource.

That distinction is essential in evaluating Wegovy. A medicine can reduce appetite or body weight without treating the loss of control, distress, and behavioral pattern that define BED. Weight change should not be used as a substitute for binge-frequency or remission outcomes.

Wegovy's approved uses do not include BED

The current FDA Wegovy prescribing information lists weight reduction, cardiovascular risk reduction in a defined population, and a liver-disease indication for the injectable formulation. It does not list BED. Using semaglutide specifically to treat BED is off-label.

The label also documents gastrointestinal adverse reactions, acute pancreatitis, gallbladder disease, acute kidney injury due to volume depletion, hypersensitivity, and other risks. Those labeled facts are relevant to safety but do not show efficacy for an eating disorder.

What the semaglutide study found

The main direct clinical report was a retrospective open-label cohort from one clinical setting. The analysis included 48 patients divided among semaglutide, lisdexamfetamine or topiramate, and combination groups. The semaglutide-only group had a larger reduction in Binge Eating Scale scores than the comparison groups. See Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.

This design cannot establish causation. Treatment was not randomly assigned, the groups were small, the study was open label, and Binge Eating Scale change is not the same as blinded diagnostic remission. Selection differences, expectations, weight change, concurrent care, and loss to follow-up can affect results. The authors concluded that further investigation was warranted, not that semaglutide had become standard BED treatment.

A case report can describe an individual response but cannot estimate benefit or harm for a population. It should not be converted into a dose, expected timeline, response percentage, or promise of remission.

What related GLP-1 research adds

A small randomized pilot tested liraglutide 3.0 mg, a different GLP-1 receptor agonist, in BED. A medication-dispensing error and small sample limited interpretation. See A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder.

That trial supports continued research on the drug class, but it cannot prove that injectable or tablet Wegovy treats BED. Different molecules, doses, study designs, and outcomes are not interchangeable.

How current BED care compares

The APA eating-disorders guideline recommends eating-disorder-focused cognitive behavioral therapy or interpersonal therapy for BED. The APA eating-disorders guideline page provides the current guideline and implementation tools.

Pharmacologic options have a separate evidence base. A 2023 biological-psychiatry guideline update identified lisdexamfetamine and topiramate as supported pharmacologic choices, with different approval status, risks, and contraindications. See World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. This does not mean either drug is appropriate for every person.

A claim-by-claim evidence grade

Clinical questions before combining obesity and BED care

The treatment team should clarify whether semaglutide is being considered for a labeled obesity, cardiovascular, or liver indication, or specifically for BED. It should also assess restrictive eating, purging, diabetes medicines, gastrointestinal disease, gallbladder and pancreatic history, pregnancy potential, mood and substance-use conditions, and the current psychotherapy plan.

Rapid appetite suppression can interact with eating-disorder symptoms in ways not captured by an obesity trial. Follow-up should measure binge episodes, loss of control, distress, regular eating patterns, medical status, and adverse effects rather than scale weight alone.

Coverage is not an evidence endpoint

A research report cannot establish insurance coverage. Plans may apply different criteria to weight-management, cardiovascular, liver, or psychiatric indications. Verify the member's current formulary and medical policy for the diagnosis actually being treated. Do not state that coverage is “unlikely” or guaranteed without a dated policy from that plan.